Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

n-3 Polyunsaturated Fatty Acids in Obesity (PUFA-ATI)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Medical University of Vienna.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
National Bank of Austria
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00760760
First received: September 25, 2008
Last updated: June 28, 2011
Last verified: June 2011

September 25, 2008
June 28, 2011
September 2008
September 2011   (final data collection date for primary outcome measure)
Adipose tissue inflammation [ Time Frame: Eight weeks of treatment ] [ Designated as safety issue: No ]
Adipose tissue inflammation [ Time Frame: end of treatment period ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00760760 on ClinicalTrials.gov Archive Site
  • Metabolic control [ Time Frame: Eight weeks of treatment ] [ Designated as safety issue: No ]
  • Dependence of effects on Pparg polymorphisms [ Time Frame: Eight weeks of treatment ] [ Designated as safety issue: No ]
  • Metabolic control [ Time Frame: end of treatment period ] [ Designated as safety issue: No ]
  • Dependence of effects on Pparg polymorphisms [ Time Frame: end of treatment period ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
n-3 Polyunsaturated Fatty Acids in Obesity
Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients

Inflammation in the adipose (fat) tissue is an important condition leading to metabolic derangements and cardiovascular disease in obese patients. n-3 polyunsaturated fatty acids exert anti-inflammatory effects and prevent adipose tissue inflammation in rodent obesity. This study tests the hypothesis that n-3 polyunsaturated fatty acids ameliorate adipose tissue inflammation in morbidly obese patients.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Basic Science
  • Adipose Tissue Inflammation
  • Morbid Obesity
  • Drug: reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)
    4g daily, 8 weeks
    Other Name: Omacor®
  • Drug: control
    equivalent amount of fat as butter
  • Experimental: n-3 PUFA
    Intervention: Drug: reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)
  • Placebo Comparator: Control
    Intervention: Drug: control

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
55
December 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Non-diabetic morbidly obese patients (BMI > 40 kg/m2) supposed to undergo bariatric surgery
  • Age 20-65 yrs

Exclusion Criteria:

  • Acute illness within the last two week
  • Known diabetes mellitus or current anti-diabetic medication
  • Acquired immunodeficiency (HIV infection)
  • Hepatitis or other significant liver disease
  • Severe or untreated cardiovascular, renal, pulmonary disease
  • Untreated or inadequately treated clinically significant thyroid disease
  • Anemia
  • Active malignant disease
  • Inborn or acquired bleeding disorder including warfarin treatment
  • Pregnancy or breast feeding
  • Drug intolerability that prohibits the use of the study drug
Both
20 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
NCT00760760
PUFA-ATI1, OeNB12735
No
Thomas M Stulnig, MD, Medical University of Vienna
Medical University of Vienna
National Bank of Austria
Principal Investigator: Thomas M Stulnig, MD Medical University of Vienna
Medical University of Vienna
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP